7 results about "Spondarthritis" patented technology

The disclosure herein relates to the development and production of novel antibodies and antigen-binding fragments thereof that bind to TL1A and are useful in the treatment, prevention, and diagnosis of diseases, disorders, or inflammation, including, for example, autoimmune diseases, including rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, systemic lupus erythematosus, asthma, ulcerative colitis, Crohn's disease, psoriasis, primary biliary cirrhosis, primary biliary cholangitis, ankylosing spondylitis, and fibrosis, including intestinal fibrosis, pulmonary fibrosis, and liver fibrosis. Some of the elements of the final antibody structure are designed de novo by a computer system and its data training set, without reference to a particular reference molecule.

The application relates to the technical field of animal models, and discloses a construction method and application of an ectopic ossification arthritis animal model. 91‑115 After being mixed and emulsified with chicken type II collagen as an antigen, animals are immunized to obtain the animal model, which is referred to as a C2V7 model. The arthritis model constructed by the application has high success rate, short time consumption and easily-obtained modeling materials. The model can simulate the onset process of arthritis with obvious ectopic ossification characteristics such as ankylosing spondylitis, enthesial-related arthritis and psoriatic arthritis, objectively reflects the pathological process and pathological characteristics of ectopic ossification arthritis, and provides a new research platform for related research.

This invention proposes a traditional Chinese medicine compound for treating ankylosing spondylitis of the kidney-deficiency and damp-heat type accompanied by gastrointestinal dysfunction, along with its preparation method, belonging to the field of traditional Chinese medicine technology. The compound consists of Smilax glabra, Bletilla striata, Paris polyphylla, Geranium wilfordii, Dioscorea hypoglauca, Patrinia scabiosaefolia, Dipsacus asper, Drynaria fortunei, Pyrola rotundifolia, Clematis chinensis, Pheretima aspergillum, Lycopodium clavatum, Corydalis yanhusuo, Paeonia lactiflora, Atractylodes macrocephala (fried), Coix lacryma-jobi (raw), Aucklandia lappa, and Glycyrrhiza uralensis. This invention combines these herbs to achieve a synergistic effect, collectively clearing heat and dampness, strengthening the spleen and kidneys, and unblocking the meridians. The overall formula addresses both strengthening the body's foundation and eliminating pathogenic factors, ensuring unobstructed meridian flow and relieving arthralgia. This compound has the functions of clearing heat and dampness, strengthening the spleen and kidneys, and unblocking the meridians. It offers a short treatment course, rapid efficacy, low recurrence rate after cure, few side effects, and is inexpensive and convenient to use for treating ankylosing spondylitis with gastrointestinal dysfunction.

This invention discloses a multi-drug composition for the treatment of ankylosing spondylitis. For the first time, this invention addresses the etiology of streptococcus-related diseases by proposing a synergistic treatment strategy combining a classic tumor necrosis factor antagonist (such as etanercept) with a narrow-spectrum antibiotic (benzathine penicillin). This approach breaks through the traditional treatment strategy that targets only the inflammatory pathway, providing a novel entry point for AS treatment.

The present invention relates to methods of treating inflammatory diseases, including methods of treating IL-23 associated diseases, in particular inflammatory diseases such as psoriasis, psoriatic arthritis or axial (spinal) spondyloarthritis (ax-SpA), including ankylosing spondylitis and radiographic negative ax-SpA, using anti-IL-23A antibodies.

The present application relates to a method for treating an autoimmune disease by an IL-17 antagonist. The present application relates to an application of an IL-17A binding agent in preparation of a drug for treating an autoimmune disease, such as rheumatoid arthritis, ankylosing spondylitis, and psoriasis, in particular, provides a method for treating inflammation or an autoimmune disease, comprising administering an effective amount of an IL-17 binding agent to a patient, wherein the administration frequency is less than once a week.